Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa

Next Previous
X
Search
Trial Profile

Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP PA01 (Primary) ; AP PA01 (Primary)
  • Indications Pseudomonal infections
  • Focus Expanded access; First in man; Therapeutic Use
  • Sponsors AmpliPhi Biosciences Corporation; Armata Pharmaceuticals

    • Most Recent Events

    • 24 May 2019 Status changed from recruiting to completed.
    • 24 Sep 2018 According to an AmpliPhi Biosciences media release, data will be presented at the in an oral abstract session Novel Therapies for Superbugs at IDWeek 2018.
    • 17 Sep 2018 Top-line clinical results were presented in an AmpliPhi Biosciences Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top